STAT
SEPTEMBER 14, 2024
BARCELONA, Spain — Patients with advanced cancers often develop a secondary condition that causes them to shed weight, making it even harder to tolerate their cancer treatments. Called cachexia, it’s an under-recognized syndrome that researchers are still trying to tease out, and one that’s attracting more interest from drugmakers.
pharmaphorum
SEPTEMBER 14, 2024
ESMO 2024 began on Friday 13th September. Prof Andres Cervantes discussed how building trust has been a several generation development, following five decades of effort in the oncological space.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
SEPTEMBER 14, 2024
BARCELONA, Spain — A widely used immunotherapy approach helped stave off disease progression in patients with a type of anal tumor, researchers reported Saturday, potentially setting up the drug for approval in a cancer that’s largely caused by human papillomavirus. The Phase 3 trial tested the PD-1 targeting antibody retifanlimab in combination with chemotherapy versus chemotherapy alone in patients with recurrent or metastatic squamous cell carcinoma of the anal canal.
BioPharma Dive
SEPTEMBER 14, 2024
Results presented at ESMO showed tumor response rates that matched the bar set by analysts for success. But they may not yet be enough to dispel doubts around TIGIT as a target.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmacy Times
SEPTEMBER 14, 2024
An ESMO 2024 presentation explores the growing role of the gut microbiome in immunotherapy response, emerging diagnostic tools such as PCR chips, and innovative therapies such as fecal microbiota transplantation and microbiome-preserving strategies to improve patient outcomes.
Pharmacy Times
SEPTEMBER 14, 2024
Not only do diverse clinical cohorts improve the strength of the data, but it improves public trust in clinicians and the medical system as a whole.
Expert insights. Personalized for you.
322 
Let's personalize your content